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Abstract
Background: The search for strategies to target ion channels for therapeutic applications has become of
increasing interest. Especially, the potassium channel KV10.1 (Ether-á-go-go) is attractive as target since this surface
protein is virtually not detected in normal tissue outside the central nervous system, but is expressed in
approximately 70% of tumors from different origins.
Methods: We designed a single-chain antibody against an extracellular region of KV10.1 (scFv62) and fused it to
the human soluble TRAIL. The KV10.1-specific scFv62 antibody -TRAIL fusion protein was expressed in CHO-K1 cells,
purified by chromatography and tested for biological activity.
Results: Prostate cancer cells, either positive or negative for KV10.1 were treated with the purified construct. After
sensitization with cytotoxic drugs, scFv62-TRAIL induced apoptosis only in KV10.1-positive cancer cells, but not in
non-tumor cells, nor in tumor cells lacking KV10.1 expression. In co-cultures with KV10.1-positive cancer cells the
fusion protein also induced apoptosis in bystander KV10.1-negative cancer cells, while normal prostate epithelial
cells were not affected when present as bystander.
Conclusions: KV10.1 represents a novel therapeutic target for cancer. We could design a strategy that selectively
kills tumor cells based on a KV10.1-specific antibody.
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Background
There is an intense effort invested into the search
for innovative therapies that can complement classical
chemotherapy, radiation and surgery to overcome the
limitations derived from chemo-resistance, toxicity of
non-specific drugs and incomplete elimination of tumor
tissue. Resistance against conventional therapies is particu-
larly relevant in prostate cancer [1]. Clonal selection
induces the development of apoptosis-resistant, androgen-
independent cells, were therapeutic prospects are relatively
poor [2].
Antibodies have become essential in the diagnostic and
therapeutic field and form one of the biggest classes of
new drugs approved for the treatment of cancer in the
last decade [3]. Single-chain antibodies (scFv) take an
important role in the field, because they are less immu-
nogenic than whole antibodies, their smaller size allows
faster and deeper penetration into solid tumors, and are
by definition recombinant proteins, therefore easier to
produce and modify. One of such modifications render-
ing novel strategies for antibody-based therapies is the
fusion to an effector molecule, to generate so-called
bifunctional antibodies.
The tumor necrosis factor-related apoptosis-inducing
ligand (TRAIL) is a promising candidate for the design of
bifunctional antibodies. TRAIL is normally present as a
membrane protein (memTRAIL) on immune effector
cells, like natural killer cells. Binding of the trimeric
TRAIL to its receptors TRAIL-R1 and TRAIL-R2 induces
caspase activation and apoptosis [4], either through the
extrinsic pathway alone or recruiting the intrinsic apopto-
tic pathway [5]. TRAIL-R1 and TRAIL-R2 have distinct
crosslinking requirements for apoptosis induction [6].
TRAIL-R1 can be activated by soluble or memTRAIL,
whereas TRAIL-R2 only responds to memTRAIL. TRAIL-
R2 has a higher binding affinity for TRAIL, resulting in
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predominant binding of TRAIL to TRAIL-R2 over TRAIL-
R1 [7].
TRAIL is involved in the elimination of transformed
cells, e.g. cancer cells or virus-infected cells, and is effec-
tive in inhibiting tumor growth in mice [8]. Importantly,
normal cells escape TRAIL-induced apoptosis for reasons
currently unclear, which may involve the expression of
three decoy receptors, TRAIL-R3, TRAIL-R4 and osteo-
protegerin [9,10]. Some cell types are resistant to TRAIL-
induced apoptosis [11], either because of a particular
TRAIL receptor profile [12], through mutations affecting
the mitochondrial apoptosis pathway in some type II can-
cer cells [13], mutations in Akt, or constitutively active
NF-B, c-FLIP or XIAP expression [14-17]. Combinational
treatments with sensitizing agents are used to make cancer
cells more susceptible to TRAIL-mediated apoptosis and
prevent the development of resistance [18-20].
memTRAIL can undergo proteolytic cleavage and
shed homotrimeric soluble TRAIL (sTRAIL). sTRAIL
has a limited apoptosis induction potential (perhaps
because TRAIL-R2 is less sensitive to sTRAIL than to
memTRAIL [6]) and a short half-life in vivo [21]. The
antibody-mediated binding of the scFv-TRAIL fusion
proteins results in a membrane-bound TRAIL that over-
comes these limitations [22-25].
Potassium channels are transmembrane proteins pri-
marily involved in controlling the resting potential and
excitability of electrically excitable cells, and in many
basic cellular processes, e.g. cell cycle or proliferation
[26], both in physiological and pathological conditions,
including cancer. In particular the complex implication
of ion channels in human prostate cancer has been
repeatedly highlighted [27].
The voltage-gated potassium channel KV10.1 (Ether-á-
go-go) shows several features that qualify it as a tumor
marker. It is practically not detected in normal healthy tis-
sue outside the CNS, but 70% of tumor cells from different
origin are positive for KV10.1 expression [26,28-30]. More-
over, it has been shown that the inhibition of KV10.1 by
channel blockers or down regulation of the expression
leads to a decreased proliferation rate of tumor cells and
impaired tumor growth in vivo [31,32]. In vivo use of
KV10.1 inhibitors reduced tumor progression, but did not
induce regression. In order to overcome this limitation, we
designed a KV10.1-specific scFv antibody fused to sTRAIL
and studied the effect in combination treatments on differ-
ent prostate cancer cell lines. This approach allows taking
advantage of the high tumor specificity of KV10.1.
Methods
Reagents
Polyclonal rabbit anti-TRAIL antibody (Abcam, Cam-
bridge, UK), monoclonal mouse anti-TRAIL antibody
(Sigma, Munich, Germany), horseradish peroxidase
conjugated antibodies (GE Healthcare, Munich,
Germany), PE-conjugated anti-TRAIL antibody,
(Abcam), anti-TRAIL receptor-1 to -4 (ENZO, Lörrach,
Germany), anti-activated-caspase-3 (Cell Signaling Tech-
nology, Lane, DA); cycloheximide (CHX), doxorubicin,
propidium iodide, saponine, G418, roscovitine, etoposide,
doxorubicin, 5-fluororuracil, cisplatin, 17-(Allylamino)-
17-demethoxy-geldanamycin (17-AAG), astemizole and
actinomycin D were from Sigma. RNase was from
Macherey-Nagel, Düren, Germany, and Zeocin was from
CAYLA-InvivoGen (Toulouse, France).
Cell culture
Human prostate cancer cell lines DU145 (ACC261), PC3
(ACC465) and LNCaP (ACC256), HEK293 (ACC305) and
CHO-K1 (ACC110) were purchased from DSMZ
(Braunschweig, Germany). hTERT-RPE1 (CRL4000) and
A375 (CRL-1619) were obtained from ATCC. The human
prostate epithelial cell line PNT2 (ECACC95012613) was
from ECACC (Salisbury, UK). Identity of prostate tumor
cell lines was confirmed through expression of specific
markers (DU145 AR-, ERa -, ERb +, PSA -, DD3 -; PC3
AR-, ERa +, ERb +, PSA -, DD3 -; LNCaP AR+, ERa-,
ERb +, PSA +, DD3 +; Prof. Paul Thelen, Department of
Urology, University Hospital Göttingen). Each cell line was
cultured in their respective recommended medium sup-
plemented with 10% FCS at 37°C in humidified 5% CO2
atmosphere. DU145-venus cells were produced by trans-
fecting pcDNA3-venus and selection of single clones with
G418 (500 μg/ml). Transfections were done with Lipofec-
tamine 2000 (Invitrogen, Darmstadt, Germany) as recom-
mended by the supplier.
Production of scFv62-TRAIL
The construction of the single-chain antibody against the
pore of KV10.1 has been described before [29]. The
sTRAIL sequence was amplified from the pEGFP-TRAIL
vector [33] (Addgene plasmid 10953) and cloned together
with scFv62 into the multiple cloning site of pSecTag2A.
The fusion protein was expressed without the tags
encoded in the pSecTag2A plasmid. A pictogram of the
construct is shown in Figure 1A. Transfected cells were
selected with Zeocin (3 μg/ml in culture medium) and sin-
gle clones were analyzed for stable secretion of scFv62-
TRAIL fusion protein. For protein expression, CHO-K1
cells transfected with the pSecTag2A-scFv62TRAIL plas-
mid were incubated at 37°C or 30°C in Panserin C6000
(PAN Biotech, Aidenbach, Germany) (after allowing
attachment for 3 h in regular medium) for five days.
Produced scFv62-TRAIL was concentrated through
Centricon YM-100 (Fisher Scientific, Schwerte, Germany)
and analyzed by size exclusion chromatography using
a HiLoad 16/60 Superdex 200 column (Amersham
Bioscience, Uppsala, Sweden). Active scFv62-TRAIL
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Figure 1 Construction, expression and characterization of scFv62-TRAIL. A) Schematic structure of the recombinant fusion construct
scFv62-TRAIL, scFv62 (30 kDa) is genetically linked through a flexible Ser-Ser-Gly-Ser-Gly linker to soluble TRAIL (21 kDa). The monomeric scFv62-
TRAIL fusion has a molecular weight of 51 kDa and the active trimer a molecular weight of ~150 kDa. B) Stable transfected CHO-K1 cells were
used to produce the scFv62-TRAIL fusion protein. Cells were seeded on cell culture flasks, after allowing cell attachment normal medium was
change into serum- and protein-free medium and cells were incubated at 37°C or 30°C. The scFv62-TRAIL yield in the medium was analyzed
after 5 days by immunoblot using an anti-TRAIL antibody. Under non-reducing conditions scFv62-TRAIL was detected as trimers (150 kDa). C)
The scFv62-TRAIL preparation was analyzed using size exclusion chromatography; the received protein peaks were analyzed by immunoblot
using an anti-TRAIL antibody. D) Stability of scFv62-TRAIL in mouse serum. The scFv62-TRAIL preparation was incubated in mouse serum at 37°C
up to 72 h and analyzed for its ability to induce apoptosis on DU145 cells in the presence of 5 μg/ml CHX (n = 3).
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concentration was estimated by ELISA using whole mono-
clonal mAb62 [29] as standard.
Caspase-3/7 assay
Caspase activity was analyzed using Caspase-Glo® 3/7
assay (Promega, Mannheim, Germany) according to
manufacturer’s instructions. Luminescence was quanti-
fied using a Victor2 plate reader (Wallac).
Flow cytometry
For analysis of apoptosis cells were treated with scFv62-
TRAIL in combination with 5 μg/ml CHX for the indi-
cated time. Combinational treatments with the different
chemotherapeutics were done with 50 U/ml scFv62-
TRAIL and the indicated concentration of the particular
agent for the indicated time. Induction of apoptosis was
measured by flow cytometry using an Annexin V-FITC/PI
staining kit (Imgenex, San Diego, CA) or Annexin V-
Alexa647 (Invitrogen). Annexin V-positive cells were
defined as a whole as apoptotic cells in all experiments,
except for the apoptosis progression analysis where we
made a distinction between early and late apoptosis.
For cell cycle analysis, cells were trypsinized, washed and
resuspended in 1 ml 137 mM NaCl, 2.7 mM KCl, 100 mM
Na2HPO4, 2 mM KH2PO4, 50 μg/ml propidium iodide,
0.3% saponine, 100 U/ml RNase A for 15 min at 4°C.
Proliferation assay
Cell proliferation was measured with AlamarBlue (Bio-
source). The dye was added to the medium (1:10) and
after 2 h incubation the fluorescence was measured in a
1420 Victor2 Multilabel Counter (Ex: 544, Em: 590 nm).
The relative proliferation was normalized to cell growth
without inhibitor.
Real-time PCR
Total RNA was obtained using RNAeasy (Qiagen,
Hilden, Germany) and first strand cDNA was produced
using SuperScript (Invitrogen). Real-time PCR was per-
formed with 100 μg cDNA in a LightCycler 480 (Roche,
Mannheim, Germany). Human transferrin receptor and
actin were used as a reference. Specific mRNA content
was determined using the LightCycler 480 software
(Roche).
Statistical analysis
Data were analyzed using GraphPad Prism and are repre-
sented as mean ± standard deviation (SD) between repli-
cates. At least two independent experiments were
performed for each analysis and the number of replicates
(n) for each experiment is indicated. Statistical signifi-
cance was evaluated by Student’s t-test; p < 0.05 was con-
sidered as significant. p values are indicated by asterisks
in the graphs (* p > 0.01; ** p > 0.001; ***, p < 0.001).
Results
Construction, expression and purification of scFv62-TRAIL
The construction of the single-chain antibody against the
pore of KV10.1 fused to alkaline phosphatase has been
described before [29]. The sequence of alkaline phospha-
tase was removed from the scFv62-AP construct and
TRAIL was cloned from the pEGFP-TRAIL vector [33]
together with a peptide linker initially into a bacterial
expression plasmid (pASK-IBA2) and transformed in the
E.coli over-expression strain BL21. After growth and
induction with anhydrotetracyclin, scFv62-TRAIL was
expressed and packed in inclusion bodies whose isolation
requires denaturing and refolding steps. The high yields
and denaturation-refolding procedure resulted in high
molecular weight aggregates of the protein (data not
shown) and was therefore not further pursued.
To produce scFv62-TRAIL in mammalian cells, we
cloned the scFv62-TRAIL into the pSecTag2A protein
expression vector, which carries the murine kappa light-
chain leader peptide upstream of the multiple cloning site,
and therefore directs the produced fusion protein through
the ER and Golgi, resulting in excretion to the culture
supernatant. Single clones were isolated from the trans-
fected CHO-K1 cells and selected for those that showed
the highest levels of secreted scFv62-TRAIL into the med-
ium. For overexpression the cells were cultured in a pro-
tein- and serum-free CHO-K1 medium and incubated at
30°C to increase the protein yield as described by [34].
This decreased the growth rate of the CHO-K1 cells but
strongly increased the scFv62-TRAIL concentration in the
supernatant (Figure 1B). This method rendered amounts
of the fusion construct in the active trimeric form suffi-
cient to perform in vitro characterizations.
To purify active and exclude the presence of non-active
monomers or high molecular weight aggregates, a size
exclusion chromatography was performed. The calculated
molecular weight of the scFv62-TRAIL is 51 kDa. The
trimeric structure has an approximate size of 150 kDa,
which could be detected on immunoblot under non-
reducing conditions (Figure 1B). To exclude the presence
of non-active monomers or dimers, size exclusion chroma-
tography was performed on a with Superdex 200 column
with optimal separation range from 10-600 kDa. The med-
ium supernatant containing the scFv62-TRAIL was loaded
onto the column and the different protein peaks were col-
lected and analyzed using immunoblot and an anti-TRAIL
antibody (Figure 1C). In the first peak we detected scFv62-
TRAIL signal, while no TRAIL signal could be found in
the later peaks containing low molecular weight proteins.
The fraction containing scFv62-TRAIL was collected, con-
centrated and sterile filtered for further analysis.
To estimate the concentration of active scFv62-
TRAIL, we performed sandwich ELISA using the recom-
binant fusion protein containing the epitope as antigen
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and detecting it by anti-TRAIL antibody. Provided that
only large molecular weight complexes, compatible with
trimetric TRAIL were purified, only multimeric con-
structs with both active antibody binding sites and
TRAIL are detected. The concentration of active
scFv62-TRAIL was expressed as equivalent units using
the whole monoclonal antibody mAb62 as standard.
To analyze the stability of the scFv62-TRAIL fusion con-
struct aliquots of the antibody solution were incubated in
mouse serum up to 72 h at 37°C. The biological activity of
the resulting material was tested on DU145 cells. After
48 h and 72 h storage in mouse serum at 37°C a reduction
in the apoptosis induction potential of 25% and 45%,
respectively, was observed (Figure 1D).
KV10.1 expression and induction of apoptosis by scFv62-
TRAIL
Prostate cancer is typically resistant against conventional
therapies [1]. We chose this model because there is evi-
dence that KV10.1 is expressed in human prostate cancer,
and a number of cell lines with detailed characterization
are available.
We used PNT2 (normal prostate epithelial cells
immortalized by SV40 with a defective replication ori-
gin), PC3 (human prostate adenocarcinoma grade IV,
androgen resistant), LNCaP (from a nodal metastasis,
androgen sensitive), DU145 (from a central nervous sys-
tem metastasis, androgen resistant) and A375 (mela-
noma). All cell lines were analyzed for expression of
KV10.1 with real-time PCR based on the Universal
Probe Library system and transferrin receptor and beta-
actin as reference genes (Figure 2A). HEK293 cells
transfected with KV10.1 (HEK h1) and hTERT-RPE1
cells were used as controls.
Among the cell lines tested, only DU145 and PNT2
showed clear KV10.1 expression. The A375 cells showed
a weak KV10.1 expression. DU145 was therefore selected
as tumor model for further studies. However this cell line
is reported to be resistant to TRAIL-induced apoptosis
due to its Bax-deficiency [35]. Therefore, scFv62-TRAIL
alone was not expected to induce apoptosis in any of the
cell lines mentioned above, because PNT2, hTERT-RPE1
and transfected HEK h1 are non-tumoral, LNCaP and
PC3 do not express the antigen on their surface and
DU145 are described to be TRAIL resistant. In the nor-
mal prostate epithelia cell line PNT2 we could also detect
KV10.1 mRNA. Indeed, treatment of the different cell
lines with scFv62-TRAIL for 18 h did not induce an
increase in apoptosis levels, assessed by Annexin V-FITC
and PI by flow cytometry analysis (Figure 2B). The A375
melanoma cell line has been reported to be sensitive to a
TRAIL-single-chain antibody fusion construct both
in vitro and in vivo [25]. This cell line was however
insensitive to our KV10.1-specific antibody TRAIL fusion,
conceivably because of low KV10.1 expression (see
below).
We also analyzed the proapoptotic activity of scFv62-
TRAIL and initially determined the induction of apopto-
sis by assaying caspase 3/7 activity after treating the
different cancer cell lines with different doses of scFv62-
TRAIL for 20 h. We observed a clear increase in caspase
activity under all conditions, independently even of the
presence of cells. This was due to the presence of apop-
tosis-independent caspase activity in the scFv62-TRAIL
preparation (Figure 2C). This endogenous activity was
confirmed by immunoblot and anti-caspase-3 antibody
detection as a 19 kDa band. Since we could not remove
this activity by extensive dialysis procedure, we exclu-
sively performed apoptosis measurements by flow cyto-
metry and Annexin/PI staining, which is independent of
caspase-3 activity.
Effects of scFv62-TRAIL in combination with other agents
Combination of TRAIL with other agents is common
strategy to sensitize otherwise resistant cells. Cyclohexi-
mide has been often used in prostate cancer cell lines as
a sensitizer, because it inhibits the cellular caspase-8
(FLICE)-like inhibitory protein (c-FLIP) and inhibitors
of apoptosis (IAP) [36-38].
Treatment of DU145 cells with 5 μg/ml CHX for
24 h leads to an increase in the fraction of cells in G1
(Figure 3A and 3B), but did not affect cell viability in
the tested time period. Treatment with scFv62-TRAIL
in combination with 5 μg/ml CHX resulted in a mas-
sive dose-dependent apoptosis induction (Figure 3C).
Over the analyzed period of 20 h, cells progressed from
early apoptosis to non-viable cells. At the end of this
period, 80% of the cells were apoptotic, and already
one half of them showed non-competent plasma mem-
brane (Figure 3D and 3E).
Other chemotherapeutic agents had been used to sen-
sitize cells to TRAIL [39-41]. The construct was tested
with conventionally used chemotherapeutic agents
(Figure 4A). Combinational treatment with scFv62-
TRAIL and etoposide or 5-fluorouracil significantly
increased the apoptosis induction by scFv62-TRAIL,
whereas the increase in apoptosis produced by combina-
tion with actinomycin D, doxorubicin or roscovitine did
not reach statistical significance. Cisplatin and 17-AAG
showed no effect. Addition of scFv62-TRAIL in combi-
nation with etoposide increased approximately 10-fold
the apoptosis induction as compared with etoposide
alone in DU154 cells.
Due to its low toxicity in the time window tested,
CHX was used subsequently as sensitizer for further
in vitro experiments.
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KV10.1- and TRAIL receptor-specific apoptosis induction
The different cell lines were treated with 50 U/ml
scFv62-TRAIL in presence of 5 μg/ml CHX for 18 hours
and the apoptosis induction was analyzed with Annexin/
PI staining and flow cytometry (Figure 4B).
As stated before, the most sensitive cell line under these
conditions was DU145. The non-cancer cell lines PNT2,
HEK h1 and hTERT-RPE1 showed no apoptosis induc-
tion. In comparison to the intense apoptosis induction in
DU145 cells, the KV10.1-negative cancer cell lines PC3
and LNCaP responded only modestly to scFv62-TRAIL
treatment. The A375 cells, which have only a low expres-
sion of KV10.1, were not affected after combinational
treatment.
To analyze the specificity of the scFv62-TRAIL and
the importance of binding to the cell surface via
KV10.1, competition experiments were performed.
When the construct was pre-incubated with a fusion
protein containing the epitope in order to block the
antibody binding sites, the effect of scFv62-TRAIL was
strongly reduced, indicating that binding to the antigen
on the cell surface is required for apoptosis induction
(Figure 4C). Moreover, the effect of scFv62-TRAIL was
abolished when a specific anti-TRAIL antibody blocked
the ligand. The single chain antibody scFv62 alone did
not have any effect. Altogether, these experiments
strongly indicate that both binding to KV10.1 on the
cell surface and an active TRAIL are required to induce
apoptosis.
Pre-incubation of the cells with whole anti-KV10.1
antibody in order to block the scFv62 recognition sites
did not inhibited the effect of scFv62-TRAIL (not
shown). This could be due to rapid internalization/recy-
cling of the surface channels.
Furthermore, we analyzed the effect of scFv62-TRAIL
on cell proliferation. We treated DU145 cells with
scFv62-TRAIL, CHX, etoposide and the KV10.1-channel
blocker astemizole [42] and analyzed the proliferation
for 72 h (Figure 4D). CHX, etoposide and astemizole
clearly reduced cell proliferation already after 24 h. But
Figure 2 KV10.1 expression analysis and apoptosis induction by scFv62-TRAIL. A) Kv10.1 mRNA levels determined by quantitative real-time
PCR. B) Apoptosis analysis using Annexin assay and flow cytometry of different cell lines treated with 50 U/ml scFv62-TRAIL or medium for 20 h
(n = 2). C) Immunoblot analysis using anti-caspase-3 antibody: 1) medium supernatant of CHO-K1, scFv62 preparation, 2) scFv62-TRAIL
preparation, 3) scFv62-TRAIL dialyzed through a 100 kDa cut-off membrane.
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Figure 3 Effect of CHX on cell cycle and in combination with scFv62-TRAIL. A) Histograms of cell cycle analysis with flow cytometer of
DU145 cells treated or non-treated with 5 μg/ml CHX and B) quantitation of cell cycle analysis. (n = 3) C) DU145 cells were treated for 18 h
with different amounts of scFv62-TRAIL in presence of 5 μg/ml CHX, and subsequently analyzed for apoptosis with Annexin-FITC/PI staining in a
flow cytometer (n = 3). D) and E) flow cytometer measurements and analysis: DU145 were treated with 50 U/ml scFv62-TRAIL in the presence of
5 μg/ml CHX and the progression of apoptosis was monitored at different time points with Annexin-FITC/PI staining (live cell: negative for both
staining, early apoptotic: Annexin-positive, late apoptotic: Annexin and PI positive).
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Figure 4 KV10.1-specific apoptosis induction. A) Annexin/PI staining and flow cytometry analysis of DU145 cells treated with scFv62-TRAIL in
combination with different chemotherapeutic agents: cisplatin (10 μM), 17-AAG (5 μM), actinomycin D (800 nM), doxorubicin (1.8 μM), etoposide
(50 μM), roscovitine (10 μM), 5-fluorouracil (100 μM), CHX (5 μg/ml) (n = 2). B) Cell lines were treated for 18 h with 50 U/ml scFv62-TRAIL in
combination with 5 μg/ml CHX and analyzed for apoptosis with Annexin/PI staining and flow cytometry (n = 2). C) Blocking assay: DU145 were
treated with scFv62-TRAIL, scFv62-TRAIL pre-incubated with anti-TRAIL antibody or scFv62-TRAIL pre-incubated with antigen, in all cases in the
presence of CHX. Alternatively, cells were pre-incubated with scFv62 for 1 h and then treated with scFv62-TRAIL and CHX. As a control, DU145
cells were treated with scFv62 preparation. Apoptosis induction was analyzed with Annexin/PI staining and flow cytometry (n = 3). D)
Proliferation assay: DU145 cells were treated with 50 U/ml scFv62-TRAIL, astemizole (4 μM), CHX (5 μg/ml) or etoposide (5 μM) and proliferation
was measured after 24, 48 and 72 h (n = 3). E) Quantitative real-time PCR analysis of the four TRAIL receptors.
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scFv62-TRAIL alone did not affect proliferation of
DU145 cells.
Analysis of TRAIL receptor expression and involvement in
apoptosis induction
In order to establish if and which combination(s) of
TRAIL receptors and KV10 are required to confer sensitiv-
ity to scFv62-TRAIL, we performed real-time PCR on the
different cell lines. The data were normalized transferrin
receptor and actin (Figure 4E). TRAIL-R3 was not or very
weakly expressed in the different cell lines, whereas
TRAIL-R4 could be detected at different expression levels
in all cells, except for PC3 and A375. All cancer cell lines
expressed both apoptosis-inducing TRAIL receptors, but
at different ratios, with LNCaP and A375 having the high-
est expression rate of TRAIL-R2. Within PC3 and DU145
cells the TRAIL-R1 expression was always slightly higher
than TRAIL-R2.
Among non-cancer cells, KV10.1 -transfected HEK h1
and hTERT-RPE1 cells showed very high TRAIL-R2 and
TRAIL-R4 expression compared to the prostate cancer
cell lines. The TRAIL receptor levels of PNT2 were rela-
tively low.
Apoptosis can be mediated via binding of TRAIL to
TRAIL-R1 or TRAIL-R2. To analyze the involvement of
these two receptors in apoptosis in DU145 cells we used
anti-TRAIL-R1 and anti-TRAIL-R2 blocking antibodies
(2 μg). After incubation of the antibodies for 1 h together
with the cells we treated them with 50 U/ml scFv62-
TRAIL in presence of 5 μg/ml CHX and analyzed the spe-
cific apoptosis (Figure 5A). Blocking of TRAIL-R1 reduced
apoptosis induction by scFv62-TRAIL by 20%, blocking of
TRAIL-R2 and both receptors resulted in a 30% apoptosis
reduction. This result indicates that apoptosis induced by
scFv62-TRAIL can be mediated by either receptor. How-
ever, the reduction of apoptosis was relatively modest; this
can indicate incomplete blocking of the TRAIL-receptors
with this approach. Therefore we decided to use siRNA to
downregulate TRAIL receptors. DU145 cells were trans-
fected with siRNA against TRAIL-R1, TRAIL-R2, or both,
and subsequently treated with scFv62-TRAIL in presence
of CHX (Figure 5B). Apoptosis induction was reduced
by 30% after downregulation of TRAIL-R1 or both death
receptors, whereas downregulation of TRAIL-R2 weakly
affected the apoptotic signal. We analyzed also the influ-
ence of siRNA-mediated inhibition on the expression of
other death receptors (Figure 5C). We detected an upregu-
lation of TRAIL-R1 when TRAIL-R2 expression was
downregulated and a slight reduction of TRAIL-R2
after downregulation of TRAIL-R1. This compensatory
mechanism when TRAIL-R2 was downregulated caused
that the total amount of messenger RNA encoding death
receptors is almost the same as in the control cells, which
could explain the weak reduction in the apoptosis
induction.
Chemotherapeutic treatment influences both TRAIL-R and
KV10.1 expression
With etoposide we could sensitize DU145 cells for
scFv62-TRAIL-induced apoptosis, while the other che-
motherapeutic agents showed no or only a weak effect.
We analyzed the influence of etoposide, 5-fluorouracil,
doxorubicin and resveratrol on the expression rate of two
death receptors TRAIL-R1 and TRAIL-R2. With quanti-
tative real-time PCR an increase in TRAIL-R1 level was
detected after 20 h etoposide treatment; doxorubicin
showed a slight increase, whereas the other agents did
not affect the expression rate (Figure 5D). The TRAIL-R2
mRNA was also only up regulated after etoposide and
doxorubicin treatment for 20 h (Figure 5E).
We also tested the effect of the different chemothera-
peutic agents on the expression of KV10.1 in DU145
cells by real-time PCR (Figure 5F). After doxorubicin
and etoposide treatment for 4 or 20 h, KV10.1 was sig-
nificantly downregulated. Treatment with 5-fluorouracil
and roscovitine for 20 h increased KV10.1 expression,
while 4 h treatment with 5-fluorouracil did not affect
the KV10.1 expression level.
Bystander effect of scFv62-TRAIL
Membrane-bound TRAIL can act through autocrine and
paracrine mechanisms. Thereby, it is possible to induce
apoptosis in cells not showing the antigen on their surface,
provided that they are in close vicinity of positive cancer
cells which provide the antigen to generate “membrane-
bound TRAIL” (bystander effect; Figure 6). To study the
likelihood for this to happen in our system, we co-cultured
the prostate cancer cell lines PC3 (KV10.1-negative) and
the normal prostate epithelia cells PNT2 (which expresses
KV10.1), with the KV10.1-positive cancer line DU145. The
DU145 cells could be identified through the stable expres-
sion of the fluorescent protein Venus (Figure 7A, upper
panel).
The co-culture was treated with scFv62-TRAIL in com-
bination with CHX. DU145 cells underwent apoptosis
with similar intensity in single and co-culture. Non-cancer
cells remained insensitive to scFv62-TRAIL also when co-
cultured (Figure 7A and 7B). In contrast, the amount of
apoptosis induction in PC3 cells was doubled when co-
cultured with DU145, indicating that scFv62-TRAIL
induces apoptosis in sensitive and bystander cancer cells,
but leaves normal cells intact (Figure 7A and 7B).
Discussion
Antibody-driven cancer therapy uses the high selectivity
of antibodies to destroy cancer cells. Therefore, a chief
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Figure 5 Influence of TRAIL receptors and KV10.1. A) DU145 cells were pre-incubated with anti-TRAIL-R1 antibody, anti-TRAIL-R2 antibody or
a mixture of both for 2 h. Cells were then treated with scFv62-TRAIL in the presence of CHX (n = 2). B) DU145 cells were transfected with siRNA
against TRAIL-R1 and/or TRAIL-R2 for 24 h and then treated with 50 U/ml scFv62-TRAIL in presence of 5 μg/ml CHX; apoptosis was measured by
flow cytometry (n = 3). C) Quantitative real-time PCR analysis: DU145 cells were transfected with siRNA against TRAIL-R1 and/or TRAIL-R2 and
analyzed for mRNA expression of death receptors. Quantitative real-time PCR analysis of D) TRAIL-R1, E) TRAIL-R2 and F) KV10.1 expression after
chemotherapeutic treatment: doxorubicin (1.8 μM), etoposide (50 μM), roscovitine (10 μM), 5-fluorouracil (100 μM).
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factor for an efficient antibody-based cancer therapy is
the targeted antigen. KV10.1 is a novel tumor marker
with diagnostic and therapeutic potential and can be
targeted by specific antibodies. We generated an anti-
body against the pore region of KV10.1 and designed a
single-chain antibody genetically linked to sTRAIL to
test the potential of such an approach.
The smaller yield of product achieved when using
CHO-K1 cells as expression system as compared to E.coli
is compensated by a higher quality of the product, proper
folding and decreased tendency to aggregate. With a
decrease of incubation temperature we increased the pro-
duction of the scFv62-TRAIL [34]. The establishment
and selection of monoclonal CHO-K1 producing the
scFv62-TRAIL antibody renders a reliable and homoge-
neous system. Tags were not added on any of the fusion
protein, since both the N-terminal end of the antibody
part and the C-terminus of TRAIL are important for
binding to the antigen or the receptor, respectively. This
approach rendered scFv62-TRAIL fusion antibody in the
active trimeric structure while preserving the binding
capacity of the antibody.
KV10.1 expression was analyzed in different prostate
cell lines and we confirmed the DU145 cells as KV10.1-
positive prostate cancer cell line. Surprisingly, we
detected KV10.1 also in normal prostate epithelia cells.
The KV10.1 expression of these cells is likely an effect of
the SV40 virus immortalization.
We initially used a 96-well format assay for active cas-
pase 3/7. This approach turned out to be unsuccessful
because of the non-specific presence of caspase-3,
apparently integrating high-molecular-weight complexes.
It is conceivable that during production of proteins,
many CHO-K1 cells undergo normal apoptosis and
apoptotic proteins of the lysed cells are released into the
medium. Caspase-3 production is not related to TRAIL
in the scFv62-TRAIL expression, because it is also
detected in the scFv62 (single chain without TRAIL)
preparations. Further apoptosis analyses were performed
using Annexin/PI staining and flow cytometry, an
active-caspase-3 independent method. It is unlikely that
the presence of caspase-3 in the supernatants is respon-
sible for the induction of apoptosis, since the scFv62
preparation did not induce apoptosis, although it con-
tains also caspase-3.
TRAIL selectively kills a variety of tumor cell lines while
sparing the majority of normal cells from apoptosis. The
TRAIL apoptosis pathway acts independently of p53,
which makes it a potentially effective weapon against
chemo- or radio-resistant tumors [43]. Cytotoxicity and
enhanced survival or even proliferation of resistant tumor
cells hampered the clinical use of sTRAIL. Combination
treatments are used to overcome the resistance and sensi-
tize resistant tumor cells for TRAIL-induced apoptosis.
Nevertheless, the short half-life and rapid blood clearance
are drawbacks of sTRAIL in vivo [8]. Our scFv62-TRAIL
antibody showed a half-life of ~72 h in mouse serum at
37°C, sufficient for in vivo use. The reported toxicity of
TRAIL to normal prostate epithelial cells seems to be a
problem of high-molecular-weight aggregates deriving
form bacterial expression systems [44] and should not be
a concern with our preparation. Using CHO-K1 cells we
were able to express correctly folded and non-aggregated
scFv62-TRAIL fusion proteins.
Different prostate cancer cell lines have been character-
ized regarding their susceptibility to TRAIL. We selected
DU145 cells because of the high KV10.1 expression level
and their known resistance to TRAIL-induced apoptosis.
As control cells we used the KV10.1-negative cell lines
PC3 and LNCaP as well as the normal epithelial cell line
PNT2. All tested cell lines are relative resistant against low
doses (50 U/ml) of the scFv62-TRAIL fusion construct as
single agent, as previously reported for other antibody-
TRAIL constructs [45,46]. Resistance of cancer cells is
mediated by multiple defects in the TRAIL signaling path-
way, e.g. downregulation of death receptors, mutations in
the mitochondrial pathway or overexpression of anti-
apoptotic proteins, like c-FLIP or XIAP [12,13,15,16].
Several studies highlight the requirement of sensitizing
agents for effective TRAIL-induced apoptosis and preven-
tion against the development of resistance [46]. We trea-
ted the prostate cells with scFv62-TRAIL in combination
with CHX, and detected a strong apoptosis induction
within 20 h in DU145 cells, whereas the KV10.1-negative
cancer and normal epithelial cells remained unaffected.
Figure 6 Bystander effect. Illustration of the scFv62-TRAIL
bystander effect. Binding of scFv62-TRAIL to KV10.1 results in the
membrane-bound form of TRAIL. Thereby, it is possible to induce
apoptosis in the same cell (autocrine) or in a neighboring cell
(paracrine) independently of KV10.1 expression. Targeting of KV10.1-
negative cells is defined as bystander effect.
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Figure 7 Determination of bystander effect. A) Upper panel. DU145 cells stably transfected with a vector expressing the fluorescent protein
Venus to identify DU145 cells in mixed cultures. Two populations are clearly distinguishable by Venus fluorescence in mixed cultures. Lower
panels. PC3 and PNT2 cells were co-cultured with DU145-venus cells and treated with 50 U/ml scFv62-TRAIL in the presence of 5 μg/ml CHX for
18 h. Apoptosis induction was analyzed with Annexin/PI staining and flow cytometry. Venus-positive (DU145 cells) are depicted in orange; green
represents PC3/PNT2 cells (bystander cells). B) Quantification of the change in apoptosis of bystander cells was calculated.
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Furthermore, the blocking experiments strongly indicated
that both binding to Kv10.1 to the cell surface and an
active TRAIL are required to induce apoptosis, and con-
firmed the specificity of scFv62-TRAIL. This observation
supports our basic idea of KV10.1-selective targeting of
cancer cells via antibody-based therapies.
We studied also the melanoma cell line A375, which
expresses KV10.1 and has been described to be sensitive
for TRAIL fused to an antibody [25]. However, we could
not detect an apoptosis-inducing effect on this cell line
neither using scFv62-TRAIL alone nor in combination
with CHX. This could be attributed to the fact that the
apoptosis-inducing effect of the antibody-TRAIL fusion
construct described by Bruyn et al. is not only based on
TRAIL, but also on the blocking of the tumorigenic
MCSP (melanoma chondroitin sulfate proteoglycan) sig-
naling mediated by the fused antibody.
We analyzed the expression levels of the four TRAIL
receptors in the different cells with real-time PCR. All
prostate cancer cells showed TRAIL-R2 expression, which
has a higher affinity for the ligand but requires a mem-
brane-bound form for apoptosis induction. This observa-
tion may explain the low efficacy of sTRAIL against
prostate cancer cells in other studies. An up-regulation of
TRAIL-R2 expression and increasing sensitivity to TRAIL
during tumor progression has been reported for prostate
cells [47]. Even though DU145 are androgen-independent
and therefore less differentiated cancer cells than LNCaP
and PC3, TRAIL-R2 expression is even lower in these
cells.
TRAIL-R4 mRNA was found in DU145 and LNCaP
cells, but not in PC3. As a non-apoptosis inducing recep-
tor TRAIL-R4 stimulates the NF-B pathway and high
NF-B levels lead to TRAIL resistance [9,48]. Using CHX
as protein synthesis inhibitor we would inhibit the NF-B-
induced protein expression and restore the sensitivity to
TRAIL-induced apoptosis in DU145 cells. CHX could also
increase sensitivity of DU145 cells by restoring the cross
talk between the extrinsic to the intrinsic pathway inter-
rupted by the loss of function of Bax [35] or by inducing
accumulation of cells in the G1 phase of the cell cycle
[49]. TRAIL-R4 and TRAIL-R2 could be involved in the
resistance against TRAIL-induced apoptosis in normal
cells, because HEK h1 and hTERT-RPE1 show high
mRNA levels of both.
Etoposide has been described to sensitize cancer cells for
TRAIL-induced apoptosis by up-regulation of TRAIL-R1,
TRAIL-R2, Bax and Bak [50]. We detected an increase in
the TRAIL-R1 and TRAIL-R2 mRNA expression level in
DU145 cells after 20 h etoposide treatment. The up-regu-
lation of the death receptors and the descript activation of
the intrinsic pathway explain the restored sensitivity to
TRAIL-induced apoptosis in DU145 cells. The cause of
resistance to TRAIL is a combination of diverse alterations
in the TRAIL signaling of the particular tumor cell, there-
fore optimized combinational treatments for scFv62-
TRAIL need to be determined for every cancer type in
further studies.
A combinational therapy of scFv62-TRAIL with etopo-
side appears to be a promising option for in vivo applica-
tion, because of the strong sensitizing effect for TRAIL in
DU145 cells. Unfortunately, we observed a downregula-
tion of KV10.1 after etoposide treatment. Careful analyses
of KV10.1 protein expression will be necessary during in
vivo long-term treatment to avoid a reduction in thera-
peutic efficiency as a result of antigen downregulation.
We wanted to investigate if scFv62-TRAIL mediates
apoptosis via TRAIL-R1 or TRAIL-R2 by blocking the
receptor with specific antibodies. It is not completely clear
which death receptor (or if both receptors) are important
for apoptosis induction via scFv62-TRAIL. However, the
expression of TRAIL-R1 and TRAIL-R2 seems to be con-
nected, because siRNA-mediated downregulation of
TRAIL-R2 in DU145 cells dramatically increases TRAIL-
R1. This can explain why we observed no decrease in
apoptosis induction after down-regulating TRAIL-R2,
because increased TRAIL-R1 expression can compensate
the TRAIL-R2 downregulation. Furthermore, this effect
also suggests an involvement of both death receptors in
the scFv62-mediated apoptosis induction. The possible
role of decoy receptors R3 and R4 cannot be discarded at
this point. Conceivably, sensitivity is determined by the
precise constellation of death and decoy receptors and not
by the abundance of a particular receptor type.
Apoptosis can be induced in an autocrine manner by
binding to TRAIL receptors on the same cell or in a para-
crine one, with binding to receptors on a neighboring
cell. Thereby also neighboring tumor cells devoid or with
low expression of the target antigen can be effectively
eliminated by the so-called bystander effect [51]. We
could detect potent bystander effect of scFv62-TRAIL
against KV10.1-negative cancer cell, whereas normal
prostate epithelia cells are not affected. This confirms the
retained tumor-selectivity of the scFv62-TRAIL antibody
construct.
Conclusions
In summary, we describe a system based on the combina-
tion of two tumor-specific features, such as KV10.1
expression and sensitivity to TRAIL. This renders an
agent able to induce apoptosis in vitro in sensitized
KV10.1-expressing prostate cancer cells and also in
neighboring cancer cells without KV10.1 on their surface,
but sparing healthy cells.
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